---
provider: claude_code
model: claude-haiku-4-5-20251001, claude-sonnet-5
cached: false
start_time: '2026-08-02T16:44:50.094972'
end_time: '2026-08-02T16:51:22.678918'
duration_seconds: 392.58
template_file: templates/disease_pathophysiology_research.md
template_variables:
  disease_name: Dilated Cardiomyopathy 2B
  mondo_id: ''
  category: Genetic
provider_config:
  timeout: 1800
  max_retries: 3
  parameters:
    allowed_domains: []
    claude_executable: claude
    skip_permissions: false
    allowed_tools:
    - WebSearch
    - WebFetch
    add_dirs: []
    timeout: 1800
    extra_args: []
run_metadata:
  models_used:
  - claude-haiku-4-5-20251001
  - claude-sonnet-5
  web_search_requests: 19
  num_turns: 34
  total_cost_usd: 2.2487646999999997
  session_id: 3ea1660e-ba17-53fa-94ba-68f4bb3ad0f5
  stop_reason: end_turn
citation_count: 17
---

## Question

# Disease Characteristics Research Template

## Target Disease
- **Disease Name:** Dilated Cardiomyopathy 2B
- **MONDO ID:**  (if available)
- **Category:** Genetic

## Research Objectives

Please provide a comprehensive research report on **Dilated Cardiomyopathy 2B** covering all of the
disease characteristics listed below. This report will be used to populate a disease knowledge
base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, **suggested databases/resources** are listed. These are the first places
you should search for information on each topic.

---

### 1. Disease Information
> **Search first:** OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

- What is the disease? Provide a concise overview.
- What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
- What are the common synonyms and alternative names?
- Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

### 2. Etiology

- **Disease Causal Factors**: What are the primary causes? (genetic, environmental, infectious, mechanistic)
- **Risk Factors**:
  > **Search first:** PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
  - Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  - Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
- **Protective Factors**:
  > **Search first:** PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
  - Genetic protective factors (protective variants, modifier alleles)
  - Environmental protective factors (diet, lifestyle, exposures that reduce risk)
- **Gene-Environment Interactions**: How do genetic and environmental factors interact to influence disease?
  > **Search first:** CTD, PubMed, PheGenI, GxE databases

### 3. Phenotypes
> **Search first:** HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide:
- **Phenotype type**: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
  > For symptoms/signs: HPO, OMIM, Orphanet, PubMed
  > For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed
  > For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed
- **Phenotype characteristics**:
  > **Search first:** OMIM, Orphanet, HPO, PubMed
  - Age of symptom onset (neonatal, childhood, adult-onset, late-onset)
  - Symptom severity (mild, moderate, severe, variable)
  - Symptom progression (stable, progressive, episodic, fluctuating)
  - Frequency among affected individuals (percentage or qualitative)
- **Quality of life impact**: Effects on daily functioning and well-being (per-phenotype when possible)
  > **Search first:** EQ-5D database, SF-36, WHO QOL databases, PubMed
- Suggest HPO (Human Phenotype Ontology) terms for each phenotype

### 4. Genetic/Molecular Information

- **Causal Genes**: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)
  > **Search first:** OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
- **Pathogenic Variants**:
  - Affected genes (gene symbols, HGNC IDs)
    > **Search first:** OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  - Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines)
    > **Search first:** ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  - Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  - Allele frequency in population databases
    > **Search first:** gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  - Somatic vs germline origin
    > **Search first:** COSMIC (somatic), ClinVar, ICGC, TCGA
  - Functional consequences (loss of function, gain of function, dominant negative)
- **Modifier Genes**: Genes that modify disease severity or expression
- **Epigenetic Information**: DNA methylation, histone modifications, chromatin changes affecting disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Chromosomal Abnormalities**: Large-scale genetic changes (aneuploidy, translocations, inversions)
  > **Search first:** DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

### 5. Environmental Information

- **Environmental Factors**: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)
  > **Search first:** CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
- **Lifestyle Factors**: Behavioral factors (smoking, diet, exercise, alcohol consumption)
  > **Search first:** CDC databases, WHO, PubMed, NHANES
- **Infectious Agents**: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)
  > **Search first:** NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

### 6. Mechanism / Pathophysiology

- **Molecular Pathways**: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)
  > **Search first:** KEGG, Reactome, WikiPathways, PathBank, BioCyc
- **Cellular Processes**: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)
  > **Search first:** Gene Ontology (GO), Reactome, KEGG, PubMed
- **Protein Dysfunction**: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)
  > **Search first:** UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
- **Metabolic Changes**: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)
  > **Search first:** KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
- **Immune System Involvement**: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)
  > **Search first:** ImmPort, Immunome Database, IEDB, Gene Ontology
- **Tissue Damage Mechanisms**: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)
  > **Search first:** PubMed, Gene Ontology, Reactome
- **Biochemical Abnormalities**: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)
  > **Search first:** BRENDA, UniProt, KEGG, OMIM, PubMed
- **Epigenetic Changes**: DNA methylation, histone modifications affecting gene expression in disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Molecular Profiling** (if available):
  - Transcriptomics/gene expression changes
    > **Search first:** GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  - Proteomics findings
    > **Search first:** PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  - Metabolomics signatures
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB, METLIN
  - Lipidomics alterations
    > **Search first:** LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  - Genomic structural features
    > **Search first:** UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
- **Advanced Technologies** (if applicable):
  - Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity)
    > **Search first:** Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  - Spatial transcriptomics findings
    > **Search first:** GEO, Spatial Research, Vizgen, 10x Genomics data
  - Multi-omics integration results
    > **Search first:** TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  - Functional genomics screens (CRISPR, RNAi)
    > **Search first:** DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe:
- The causal chain from initial trigger to clinical manifestation
- Which mechanisms are upstream vs downstream
- What cell types and biological processes are involved
- Suggest GO terms for biological processes and CL terms for cell types

### 7. Anatomical Structures Affected

- **Organ Level**:
  - Primary organs directly affected
  - Secondary organ involvement (complications, secondary effects)
  - Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)
  > **Search first:** Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
- **Tissue and Cell Level**:
  - Specific tissue types affected (epithelial, connective, muscle, nervous)
  - Specific cell populations targeted (with Cell Ontology terms)
  > **Search first:** Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
- **Subcellular Level**:
  - Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)
  > **Search first:** Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
- **Localization**:
  - Specific anatomical sites (with UBERON terms)
    > **Search first:** FMA, Uberon, NeuroNames (for brain), SNOMED CT
  - Lateralization (unilateral, bilateral, asymmetric)
    > **Search first:** HPO, clinical literature, imaging databases

### 8. Temporal Development

- **Onset**:
  - Typical age of onset (congenital, pediatric, adult, geriatric)
  - Onset pattern (acute, subacute, chronic, insidious)
  > **Search first:** OMIM, Orphanet, HPO, PubMed
- **Progression**:
  - Disease stages (early, intermediate, advanced, end-stage)
    > **Search first:** Cancer Staging Manual (AJCC), WHO classifications, PubMed
  - Progression rate (rapid, slow, variable)
  - Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  - Disease duration (self-limited, chronic lifelong)
  > **Search first:** Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
- **Patterns**:
  - Remission patterns (spontaneous, treatment-induced)
    > **Search first:** Clinical trial databases, disease registries, PubMed
  - Critical periods (time windows of vulnerability or opportunity for intervention)
    > **Search first:** PubMed, developmental biology databases, clinical guidelines

### 9. Inheritance and Population

- **Epidemiology**:
  - Prevalence (cases per 100,000 at given time)
  - Incidence (new cases per 100,000 per year)
  > **Search first:** Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
- **For Genetic Etiology**:
  - Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic)
    > **Search first:** OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  - Penetrance (complete, incomplete, age-dependent)
    > **Search first:** ClinVar, OMIM, PubMed, ClinGen
  - Expressivity (variable, consistent)
    > **Search first:** OMIM, ClinVar, PubMed
  - Genetic anticipation (increasing severity in successive generations)
    > **Search first:** OMIM, PubMed (especially for repeat expansion disorders)
  - Germline mosaicism
    > **Search first:** ClinVar, OMIM, genetic counseling literature, PubMed
  - Founder effects (population-specific mutations)
    > **Search first:** gnomAD, population genetics databases, PubMed
  - Consanguinity role
    > **Search first:** OMIM, population studies, genetic counseling resources
  - Carrier frequency
    > **Search first:** gnomAD, carrier screening databases, GeneReviews, GTR
- **Population Demographics**:
  - Affected populations (ethnic or demographic groups with higher prevalence)
    > **Search first:** gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  - Geographic distribution (endemic areas, regional variation)
    > **Search first:** WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  - Geographic distribution of specific variants
  - Sex ratio (male:female)
    > **Search first:** Disease registries, OMIM, PubMed, epidemiological databases
  - Age distribution of affected individuals
    > **Search first:** CDC, disease registries, SEER, Orphanet

### 10. Diagnostics

- **Clinical Tests**:
  - Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays)
    > **Search first:** LOINC, LabTests Online, PubMed
  - Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers)
    > **Search first:** FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  - Imaging studies (X-ray, CT, MRI, PET, ultrasound)
    > **Search first:** RadLex, DICOM, Radiopaedia, imaging databases
  - Functional tests (pulmonary function, cardiac stress tests)
    > **Search first:** LOINC, clinical guidelines, PubMed
  - Electrophysiology (EEG, EMG, ECG, nerve conduction studies)
    > **Search first:** LOINC, clinical neurophysiology databases, PubMed
  - Biopsy findings (histopathology, immunohistochemistry)
    > **Search first:** SNOMED CT, College of American Pathologists resources, PubMed
  - Pathology findings (microscopic examination)
    > **Search first:** SNOMED CT, Digital Pathology databases, PubMed
- **Genetic Testing**:
  > **Search first:** GTR (Genetic Testing Registry), GeneReviews, ClinGen
  - Overview of recommended genetic testing approach
  - Whole genome sequencing (WGS) utility
    > **Search first:** GTR, ClinVar, GEL (Genomics England), gnomAD
  - Whole exome sequencing (WES) utility
    > **Search first:** GTR, ClinVar, OMIM, GeneMatcher
  - Gene panels (which panels, which genes)
    > **Search first:** GTR, ClinVar, laboratory-specific databases
  - Single gene testing
    > **Search first:** GTR, ClinVar, OMIM, GeneReviews
  - Chromosomal microarray (CMA)
    > **Search first:** DECIPHER, ClinVar, dbVar, ECARUCA
  - Karyotyping
    > **Search first:** Chromosome Abnormality Database, ClinVar, cytogenetics resources
  - FISH
    > **Search first:** ClinVar, cytogenetics databases, PubMed
  - Mitochondrial DNA testing
    > **Search first:** MITOMAP, MSeqDR, ClinVar, GTR
  - Repeat expansion testing
    > **Search first:** GTR, ClinVar, repeat expansion databases, PubMed
- **Omics-Based Diagnostics** (if applicable):
  - RNA sequencing / transcriptomics
    > **Search first:** GEO, ArrayExpress, GTEx, RNA-seq databases
  - Proteomics
    > **Search first:** PRIDE, ProteomeXchange, FDA Biomarker database
  - Metabolomics
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB
  - Epigenomics
    > **Search first:** GEO, ENCODE, Roadmap Epigenomics, MethBase
  - Liquid biopsy
    > **Search first:** COSMIC, ClinVar, liquid biopsy databases, PubMed
- **Clinical Criteria**:
  - Standardized diagnostic criteria (DSM, ICD, society guidelines)
    > **Search first:** DSM-5, ICD-11, clinical society guidelines, UpToDate
  - Differential diagnosis (other conditions to rule out, with distinguishing features)
    > **Search first:** DynaMed, UpToDate, clinical decision support systems
- **Screening**:
  - Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening)
    > **Search first:** ACMG recommendations, CDC newborn screening, GTR

### 11. Outcome/Prognosis

- **Survival and Mortality**:
  - Survival rate (5-year, 10-year, overall)
    > **Search first:** SEER, cancer registries, disease-specific registries, PubMed
  - Life expectancy (with and without treatment if applicable)
    > **Search first:** Orphanet, disease registries, actuarial databases, PubMed
  - Mortality rate
    > **Search first:** CDC, WHO, GBD, national mortality databases
  - Disease-specific mortality (deaths directly attributable to disease)
    > **Search first:** Disease registries, CDC Wonder, GBD, PubMed
- **Morbidity and Function**:
  - Morbidity (disease-related disability and health impacts)
    > **Search first:** GBD, WHO, disability databases, PubMed
  - Disability outcomes (long-term functional impairments)
    > **Search first:** ICF (International Classification of Functioning), disability registries
  - Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools)
    > **Search first:** EQ-5D database, SF-36, PROMIS, PubMed
- **Disease Course**:
  - Complications (secondary problems: infections, organ failure, etc.)
    > **Search first:** ICD codes, disease registries, clinical databases, PubMed
  - Recovery potential (likelihood and extent of recovery, with vs without treatment)
    > **Search first:** Natural history studies, rehabilitation databases, PubMed
- **Prediction**:
  - Prognostic factors (age, disease severity, biomarkers, treatment response)
    > **Search first:** Prognostic models databases, clinical calculators, PubMed
  - Prognostic biomarkers (molecular markers predicting disease course)
    > **Search first:** FDA Biomarker database, PubMed, cancer prognostic databases

### 12. Treatment

- **Pharmacotherapy**:
  - Pharmacological treatments (drug names, drug classes, mechanisms of action)
    > **Search first:** DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  - Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity)
    > **Search first:** PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
- **Advanced Therapeutics**:
  - Gene therapy (viral vectors, CRISPR, gene replacement, gene editing)
    > **Search first:** ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  - Cell therapy (stem cell transplant, CAR-T, cellular therapeutics)
    > **Search first:** ClinicalTrials.gov, FDA cell therapy database, FACT standards
  - RNA-based therapies (ASOs, siRNA, mRNA therapies)
    > **Search first:** ClinicalTrials.gov, FDA approvals, PubMed
  - Targeted therapies (treatments directed at specific molecular targets)
    > **Search first:** My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  - Immunotherapies (checkpoint inhibitors, monoclonal antibodies)
    > **Search first:** Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
- **Surgical and Interventional**:
  - Surgical interventions (types of surgery, timing, outcomes)
    > **Search first:** CPT codes, surgical registries, clinical guidelines, PubMed
- **Supportive and Rehabilitative**:
  - Supportive care (symptom management, pain control, nutrition)
    > **Search first:** Clinical guidelines, Cochrane Library, PubMed
  - Rehabilitation (physical therapy, occupational therapy, speech therapy)
    > **Search first:** Rehabilitation medicine databases, clinical guidelines, PubMed
- **Experimental**:
  - Experimental treatments in clinical trials (with NCT identifiers if available)
    > **Search first:** ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
- **Treatment Outcomes**:
  - Treatment response rates
    > **Search first:** Clinical trial databases, FDA reviews, systematic reviews, PubMed
  - Side effects and adverse events
    > **Search first:** FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
- **Treatment Strategy**:
  - Treatment algorithms (clinical pathways, decision trees)
    > **Search first:** Clinical practice guidelines, NCCN Guidelines, UpToDate
  - Combination therapies
    > **Search first:** ClinicalTrials.gov, treatment guidelines, PubMed
  - Personalized medicine approaches (genotype-guided treatment)
    > **Search first:** My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

### 13. Prevention

- **Prevention Levels**:
  - Primary prevention (preventing disease occurrence: vaccination, risk factor modification)
    > **Search first:** CDC, WHO, USPSTF recommendations, Cochrane Library
  - Secondary prevention (early detection and treatment: screening programs, early intervention)
    > **Search first:** USPSTF, CDC screening guidelines, WHO
  - Tertiary prevention (preventing complications in those with disease)
    > **Search first:** Clinical guidelines, disease management protocols, PubMed
- **Immunization**: Vaccine strategies (if applicable)
  > **Search first:** CDC vaccine schedules, WHO immunization, FDA vaccine database
- **Screening and Early Detection**:
  - Screening programs (population-based: newborn screening, cancer screening)
    > **Search first:** CDC screening programs, USPSTF, cancer screening databases
  - Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing)
    > **Search first:** ACMG recommendations, ACOG guidelines, GTR
  - Risk stratification (identifying high-risk individuals for targeted prevention)
    > **Search first:** Risk prediction models, clinical calculators, PubMed
- **Behavioral Interventions**: Lifestyle modifications to reduce risk
  > **Search first:** CDC, WHO, behavioral intervention databases, Cochrane Library
- **Counseling**: Genetic counseling (risk assessment, family planning guidance)
  > **Search first:** NSGC resources, ACMG guidelines, GeneReviews
- **Public Health**:
  - Public health interventions (sanitation, vector control, health education)
    > **Search first:** CDC, WHO, public health databases, PubMed
  - Environmental interventions (reducing environmental risk factors)
    > **Search first:** EPA databases, WHO environmental health, PubMed
- **Prophylaxis**: Preventive medications or procedures
  > **Search first:** Clinical guidelines, FDA approvals, PubMed

### 14. Other Species / Natural Disease

- **Taxonomy**: Species affected (with NCBI Taxon identifiers)
  > **Search first:** NCBI Taxonomy
- **Breed**: Specific breeds affected (with VBO identifiers if applicable)
  > **Search first:** VBO (Vertebrate Breed Ontology)
- **Gene**: Orthologous genes in other species (with NCBI Gene IDs)
  > **Search first:** NCBI Gene
- **Natural Disease**:
  - Naturally occurring disease in other species (companion animals, wildlife)
    > **Search first:** OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  - Veterinary relevance and importance in animal health
    > **Search first:** OMIA, veterinary databases, PubMed
- **Comparative Biology**:
  - Comparative pathology (similarities and differences across species)
    > **Search first:** OMIA, comparative pathology databases, PubMed
  - Evolutionary conservation of disease mechanisms
    > **Search first:** HomoloGene, OrthoMCL, Alliance of Genome Resources
- **Transmission** (if applicable):
  - Zoonotic potential
    > **Search first:** CDC zoonotic diseases, WHO zoonoses, GIDEON
  - Cross-species susceptibility
    > **Search first:** NCBI Taxonomy, veterinary databases, PubMed

### 15. Model Organisms

- **Model Types**:
  - Model organism type (mammalian, invertebrate, cellular, in vitro)
    > **Search first:** Alliance of Genome Resources, model organism databases
  - Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs)
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  - Induced models (drug treatment, surgical intervention, environmental manipulation)
    > **Search first:** MGI, model organism databases, PubMed
- **Genetic Models**:
  - Types available (knockout, knock-in, transgenic, conditional, humanized)
    > **Search first:** MGI, IMPC, KOMP, EuMMCR, IMSR
- **Model Characteristics**:
  - Phenotype recapitulation (how well model reproduces human disease features)
    > **Search first:** Model organism databases, comparative studies, PubMed
  - Model limitations (aspects of human disease not captured)
    > **Search first:** Model organism databases, PubMed, review articles
- **Applications**:
  - Research applications (what aspects of disease can be studied)
    > **Search first:** Model organism databases, PubMed
- **Resources**:
  - Model databases
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

---

## Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic and clinical claims
- Prioritize recent reviews and landmark papers
- Include direct quotes from abstracts where possible to support key statements
- Distinguish evidence source types: human clinical, model organism, in vitro, computational

## Output Format

Structure your response as a comprehensive narrative organized by the sections above.
For each section, provide:
- Factual content with specific details (numbers, percentages, gene names, variant nomenclature)
- Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable
- Evidence citations with PMIDs
- Direct quotes from abstracts to support key claims
- Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with:
- Pathophysiology descriptions with causal chains
- Gene/protein annotations (HGNC, GO terms)
- Phenotype associations (HP terms) with frequencies
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Treatment annotations (NCIT terms)
- Evidence items with PMIDs and exact abstract quotes
- Epidemiology, prognosis, diagnostic, and prevention information
- Animal model descriptions with phenotype recapitulation details


## Output

I now have sufficient primary-literature data to compile the comprehensive report.

# Dilated Cardiomyopathy 2B (CMD2B): Comprehensive Research Report

## Executive Summary

Dilated Cardiomyopathy, 2B (CMD2B) is an **ultra-rare, autosomal recessive** form of dilated cardiomyopathy (DCM) caused by a homozygous missense mutation in **GATAD1** (GATA zinc finger domain-containing protein 1), a chromatin-modifying protein. It was described in a single consanguineous Norwegian-American family reported by Theis et al. in 2011 (PMID:21965549), making it one of the rarest molecularly defined DCM subtypes in the OMIM catalog. The discovery is mechanistically notable because it implicated, for the first time, an inherited defect in **histone H3K4 trimethylation (H3K4me3) reading** as a cause of human heart failure — a form of "epigenetic dysregulation" rather than a defect in a sarcomeric, cytoskeletal, or ion-channel protein as seen in most other genetic DCMs.

---

## 1. Disease Information

**Overview:** CMD2B is a form of dilated cardiomyopathy — a myocardial disease characterized by left ventricular (or biventricular) dilation and systolic dysfunction not explained by abnormal loading conditions or coronary artery disease — that segregates as an **autosomal recessive trait** in a single reported kindred, distinguishing it from the more common autosomal dominant DCM loci (e.g., CMD1A/*LMNA*, CMD1G/*TTN*).

**Key identifiers:**
- **OMIM:** #614672 — CARDIOMYOPATHY, DILATED, 2B; CMD2B (phenotype); *614518 — GATA ZINC FINGER DOMAIN-CONTAINING PROTEIN 1; GATAD1 (gene)
- **Gene:** GATAD1, HGNC:23709, chromosome 7q21.3
- **Parent/umbrella disease:** Dilated cardiomyopathy, MONDO:0005021; HP:0001644 "Dilated cardiomyopathy"
- **MeSH:** D002311 (Cardiomyopathy, Dilated) — the CMD2B subtype itself is not separately indexed in MeSH/ICD-10/ICD-11/Orphanet, which lack subtype-specific codes for this ultra-rare monogenic entity; it falls under **ICD-10 I42.0** (Dilated cardiomyopathy) generically.
- **Orphanet:** No dedicated ORPHA code was found for CMD2B specifically; it would fall under the broader "Familial isolated dilated cardiomyopathy" umbrella (ORPHA:154).
- **Synonyms:** CMD2B; Cardiomyopathy, Dilated, 2B; GATAD1-related dilated cardiomyopathy; Autosomal recessive dilated cardiomyopathy due to GATAD1 mutation.

**Evidence source note:** Nearly all disease-specific information available is derived from **a single aggregated pedigree-level clinical genetics study** (one extended family, 3 affected homozygotes, 13 heterozygous carriers, 8 unaffected homozygous wild-type relatives) rather than population-level EHR/registry data — an important caveat for prevalence and phenotype-frequency claims below (Theis et al. 2011, PMID:21965549, *Circ Cardiovasc Genet* 4(6):585–594).

---

## 2. Etiology

**Disease causal factor:** A single identified cause — the **homozygous GATAD1 c.304T>C (p.Ser102Pro; "S102P") missense mutation** in exon 2 of GATAD1, located within/adjacent to the protein's N-terminal GATA-type zinc finger domain. The mutation:
- Substitutes a polar hydroxyl serine for a nonpolar cyclic proline at a highly conserved residue across species.
- Is absent from HapMap, 1000 Genomes, the Human Gene Mutation Database, and was screened against **1,558 control chromosomes** (474 ethnically matched control individuals plus a separate 273-proband unrelated DCM cohort) with zero occurrences — supporting pathogenicity via absence from population databases (PMID:21965549).
- Screening of the 5 exons of GATAD1 in 273 additional unrelated DCM probands found **no additional mutations**, indicating GATAD1 is a rare cause of DCM even among genetically unsolved autosomal recessive-appearing cases.

**Genetic risk factors:**
- **Causal variant:** Biallelic (homozygous) GATAD1 S102P is necessary; this is a fully penetrant recessive allele in the reported kindred — all 3 homozygotes were affected (2 overt DCM, 1 intermediate phenotype), while all 13 heterozygous carriers (including elderly individuals) showed **no evidence of myocardial disease**, indicating no dominant/haploinsufficiency effect of a single mutant allele in humans (contrast with the zebrafish model, below).
- **Consanguinity** is the key demographic risk factor: the proband's parents were first cousins, enabling homozygosity for a rare recessive allele — illustrating the classical mechanism by which consanguinity unmasks recessive Mendelian cardiomyopathy.
- **Modifier/susceptibility considerations:** The brother (subject III.6), also homozygous S102P, showed only an "intermediate phenotype" (isolated left ventricular enlargement without progression to overt heart failure, eventually reaching borderline EF 50% at age 68 before dying of unrelated cancer at 73) — suggesting incomplete penetrance to the full DCM phenotype, possible sex-modifying effects, or stochastic/environmental modifiers, though the small pedigree size precludes formal modifier-gene analysis.
- **No GWAS Catalog, ClinGen, or PheGenI hits** exist for GATAD1 given the extreme rarity (single-family Mendelian discovery, not a common-variant susceptibility locus).

**Environmental/lifestyle risk and protective factors:** None specifically documented for CMD2B. General DCM environmental contributors (alcohol, viral myocarditis, chemotherapy, peripartum state) were not implicated in this family, whose disease is presented as monogenic and Mendelian.

**Gene-environment interactions:** Not established in humans. Notably, the zebrafish *gatad1* knockout model (Ta et al., *J Cardiovasc Dev Dis* 2016; PMID:28955713) showed **no baseline cardiac phenotype**, requiring superimposed environmental/toxic stress (chronic ethanol exposure during embryogenesis plus a high-cholesterol diet in adulthood) to unmask a heart-failure-like phenotype (reduced swimming capacity, reduced survival, induction of the fetal cardiac stress genes *nppb* and *vmhc*) — an animal-model suggestion (not yet validated in humans) that gene-environment interaction may modulate expressivity of GATAD1-associated cardiomyopathy.

---

## 3. Phenotypes

Because CMD2B is known from only 3 confirmed homozygous individuals, "frequency" percentages below reflect **counts within this single family, not population-based frequency estimates** — this should be flagged in curation as `evidence_source: HUMAN_CLINICAL` from a single pedigree, not epidemiological data.

| Phenotype | Type | HPO suggestion | Onset/course | Occurrence in reported family |
|---|---|---|---|---|
| Dilated cardiomyopathy / LV enlargement with reduced EF | Clinical sign | **HP:0001644** Dilated cardiomyopathy | Adult onset (50, 53 yrs); progressive but slowly so (decades-long survival) | 2/3 homozygotes (both female) |
| Reduced left ventricular ejection fraction | Lab/imaging finding | **HP:0012664** Reduced ejection fraction (or HP:0001635 Congestive heart failure) | Severe at diagnosis (EF 21%) in proband, moderate (EF 40%) in sister | 2/3 |
| Idiopathic left ventricular enlargement (intermediate/subclinical phenotype) | Imaging finding | **HP:0034194** Left ventricular dilatation (or "LV enlargement" mapped generically) | Later onset (57 yrs), non-progressive to overt HF | 1/3 (brother) |
| Congestive heart failure, NYHA class II | Clinical sign | **HP:0001635** Congestive heart failure | Chronic, stable on medical therapy for 20+ years | 2/3 |
| Cardiomegaly | Imaging finding | **HP:0001640** Cardiomegaly | At presentation | 1/3 (proband) |
| Myocyte hypertrophy (biopsy) | Histopathology | **HP:0025423** (or descriptive: myocardial hypertrophy) | At diagnosis | 1/3 (endomyocardial biopsy, proband) |
| Mild focal interstitial fibrosis | Histopathology | **HP:0001681** Cardiac fibrosis (closest term) | At diagnosis | 1/3 |
| Persistent atrial fibrillation | Arrhythmia | **HP:0005110** Atrial fibrillation | Developed during follow-up, required AV-node ablation + pacemaker | 1/3 (sister) |
| Abnormal cardiomyocyte nuclear morphology (globular vs. spindle-shaped nuclei) | Histopathology (unique to this disease) | No precise HPO term (closest: HP:0012404 Abnormal nuclear morphology) | Structural, present at biopsy | 1/1 tested (proband) |

**Severity/progression:** Disease course was notably **indolent** — the proband survived >24 years post-diagnosis on standard heart-failure pharmacotherapy without transplant; her sister survived >23 years. This contrasts with some other monogenic DCMs (e.g., LMNA, FLNC, RBM20) that carry higher arrhythmic/sudden-death risk and more aggressive courses.

**Quality of life impact:** Not formally measured (no EQ-5D/SF-36 data reported); qualitatively, both affected sisters remained NYHA class II (mild-to-moderate symptomatic limitation) for decades rather than progressing to advanced/refractory heart failure.

---

## 4. Genetic/Molecular Information

- **Causal gene:** GATAD1 (HGNC:23709; Entrez Gene 57798; UniProt Q8WUU5, 269 amino acids), chromosome **7q21.3** (physically within the 7.3 Mb critical region defined by homozygosity mapping between markers *D7S669* and *D7S515*).
- **Pathogenic variant:** NM_021167.5(GATAD1):c.304T>C (p.Ser102Pro). Also referenced under ClinVar as related to variant entries for GATAD1 in the context of "Dilated cardiomyopathy 2B" (e.g., ClinVar RCV000861207 lists a distinct His32Gln GATAD1 variant tested against the same disease term, reflecting subsequent diagnostic-lab curation/testing rather than a second confirmed disease-causing family).
- **Variant classification:** Functionally treated as pathogenic in the primary report based on: absence from population databases (0/1,558 chromosomes), segregation with disease in a homozygous-recessive pattern across three generations, evolutionary conservation of the residue, and abnormal protein localization/nuclear morphology in patient myocardium — though it predates modern ACMG/AMP formal classification and (per surveys) remains a "limited evidence" gene-disease association given the single-family origin.
- **Zygosity:** Homozygous (biallelic) in all 3 affected individuals; heterozygous carriers (n=13, including elderly relatives) were clinically unaffected — consistent with a **fully recessive** mechanism in humans, i.e., not haploinsufficient.
- **Somatic vs. germline:** Germline (heritable, segregating in a Mendelian pedigree).
- **Functional consequence:** The mutant S102P protein is **still expressed** in patient myocardium (ruling out a simple loss-of-protein/null mechanism); rather, immunohistochemistry showed a **marked disturbance in its subcellular distribution** and was associated with an abnormal ("globular" rather than elongated spindle-shaped) cardiomyocyte nuclear morphology — suggesting a mislocalization/dominant-negative-at-the-molecular-level (but recessive-at-the-organismal-level) mechanism affecting chromatin complex assembly rather than simple loss of GATAD1 protein.
- **Modifier genes:** None formally identified; incomplete penetrance in the one homozygous male relative (isolated LV enlargement, not overt DCM) raises the possibility of unidentified modifiers or sex effects, but this is speculative given n=3.
- **Epigenetic information (central to this disease's mechanism, not merely a modifier):** GATAD1 is itself a chromatin "reader" component — see Mechanism section below.
- **Chromosomal abnormalities:** None; this is a point mutation, not a structural/copy-number variant.
- **Population genetics:** No gnomAD-based constraint metrics were specifically reported in the sources reviewed; GATAD1 has not been highlighted as a strongly LOF-constrained gene in general constraint databases, consistent with a recessive rather than haploinsufficient disease mechanism (heterozygous carriers tolerate loss of one functional allele).

---

## 5. Environmental Information

No specific environmental toxin, occupational exposure, or infectious trigger has been implicated in the human CMD2B family — the disease is presented as a purely monogenic Mendelian cardiomyopathy. The only environmental-interaction data come from the zebrafish model, where **ethanol exposure during embryogenesis** and a **4% high-cholesterol diet** in adulthood were required to unmask a cardiac phenotype in *gatad1*-null fish (PMID:28955713) — this is model-system evidence only and has not been validated as relevant to human GATAD1 carriers (a candidate `HUMAN_MODEL_MISMATCH` consideration for KB curation, since translational validity of the alcohol/cholesterol zebrafish stressors to the human disease course is untested).

---

## 6. Mechanism / Pathophysiology

This is the scientifically distinctive aspect of CMD2B: it is proposed as the first human Mendelian cardiomyopathy attributable to **inherited epigenetic/chromatin-reader dysregulation** rather than a structural sarcomeric/cytoskeletal/ion-channel defect.

**Causal chain (as proposed by Theis et al. 2011, PMID:21965549):**
1. **Trigger (molecular):** Homozygous GATAD1 S102P mutation alters a conserved residue near the N-terminal GATA-type zinc finger domain.
2. **Molecular pathway/protein dysfunction:** GATAD1 is a subunit of a chromatin-modifying complex that recognizes/binds **histone H3 trimethylated at lysine 4 (H3K4me3)** — a canonical "active promoter" epigenetic mark. The complex includes **KDM5A** (an H3K4me3 demethylase) and **EMSY**, and — critically for the heart-failure link — human **HDAC1 and HDAC2** are reported binding partners of GATAD1. Mice with cardiac-specific conditional double knockout of *Hdac1*/*Hdac2* develop dilated cardiomyopathy, providing independent support that this general chromatin-regulatory node (H3K4me3-reader/HDAC axis) is heart-failure-relevant.
3. **Cellular consequence:** In the proband's myocardium, the mutant GATAD1-S102P protein was still present (excluding simple loss of protein) but showed **abnormal subcellular/extranuclear distribution**, and cardiomyocyte nuclei displayed **abnormal globular morphology** (vs. normal elongated spindle shape) — implying disrupted chromatin organization/nuclear architecture.
4. **Tissue/organ consequence:** Progressive myocyte hypertrophy with mild interstitial fibrosis on biopsy, culminating in **ventricular dilation and impaired systolic function** (i.e., the DCM phenotype), congestive heart failure, and (in one case) atrial fibrillation.
5. **Broader epigenetic-disease link:** The authors cite that a distinct **H3K4me3 epigenetic profile has separately been reported in left ventricular myocardium of (non-genetic) DCM patients** compared with normal hearts, supporting a general — not just GATAD1-specific — role for this histone mark in heart failure pathophysiology; the GATAD1 finding provides a genetic/causal anchor for that broader epigenomic observation.

**Suggested ontology terms:**
- **GO Molecular Function:** GO:0008270 zinc ion binding; GO:0003677 DNA binding; histone-reader activity terms under the broader chromatin-binding GO tree.
- **GO Biological Process:** GO:0006325 chromatin organization; GO:0006338 chromatin remodeling; GO:0006357 regulation of transcription by RNA polymerase II.
- **GO Cellular Component:** GO:0005634 nucleus; nucleoplasm/chromatin-associated complex terms.
- **CL (cell type):** CL:0000746 cardiac muscle cell (cardiomyocyte).
- **UniProt/InterPro:** GATA-type zinc finger domain (as annotated on Q8WUU5).

**Model-system caveat (important for curation, `HUMAN_MODEL_MISMATCH`):** Two independent mammalian/vertebrate models give **discordant** results relative to the human recessive Mendelian phenotype:
- The **zebrafish knockout** (TALEN-generated frameshift null alleles) required combined chronic ethanol + high-cholesterol stress to show a heart-failure-like phenotype (reduced swimming capacity, reduced survival after ~7 months of age, induction of *nppb*/*vmhc* fetal cardiac genes), and the authors interpreted this as consistent with a **haploinsufficient** contribution, while separately noting that transgenic zebrafish expressing the human S102P missense allele showed only "a tendency" toward heart-failure phenotypes, potentially via a **dominant-negative** mechanism (PMID:28955713).
- A **2024 mouse study** using a cardiomyocyte-specific *Gatad1* conditional knockout found **no cardiomyopathy phenotype** at baseline aging to 18 months, nor after pressure-overload stress (transverse aortic constriction), and — notably — **no abnormal nuclear morphology**, unlike the human patient's myocardium (PMID:39641830). The authors conclude cardiomyocyte-autonomous Gatad1 loss alone does not reproduce the human disease, suggesting either a non-cell-autonomous requirement, a need for the specific missense (not null) allele, species differences, or an additional co-factor/second-hit not captured by simple gene deletion.
- A separate but mechanistically informative 2024–2025 study found that **Gatad1 in mouse cardiomyocytes regulates metabolic gene transcription during ischemia-reperfusion injury** — directly repressing fatty-acid oxidation genes *Acaa2* and *Acadm* while indirectly promoting the glucose-oxidation gene *Pdha1*, modulating cardiomyocyte apoptosis after ischemic injury and mediating the cardioprotective effect of sphingosylphosphorylcholine (SPC) (ScienceDirect/Free Radical Biology and Medicine, 2025) — supporting a genuine, if context-dependent (stress-inducible), transcriptional role for GATAD1 in the heart, distinct from steady-state cardiomyopathy causation.
- A further preliminary/unverified lead: GATAD1 was also reported as **overexpressed in myocardium of female idiopathic DCM patients compared to males** in a cardiac-specific microarray study, proposed as a candidate contributor to sex-related differences in idiopathic DCM gene expression — this is a correlative transcriptomic finding, not a causal claim, and needs independent verification before curation.

**Not supported / caution:** Some secondary databases (e.g., GeneCards aggregation) list GATAD1 as associated with "Heimler Syndrome 1." **This appears to be a database-aggregation artifact and should NOT be curated as a genuine GATAD1 disease association** — the authoritative literature (Ratbi et al. 2015, PMC4596894) establishes Heimler syndrome as caused by hypomorphic **PEX1** and **PEX6** mutations (peroxisome biogenesis genes), unrelated to GATAD1. Flag this as a **Named Entity/Association Confusion** risk if encountered again during curation.

---

## 7. Anatomical Structures Affected

- **Organ level (primary):** Heart — specifically the **left ventricle** (dilation, reduced ejection fraction; UBERON:0002084 heart left ventricle), with cardiac conduction system involvement in one case (AV node ablation for atrial fibrillation).
- **Secondary/systemic:** Congestive heart failure produces downstream systemic effects (fluid retention, reduced exercise tolerance) typical of any DCM, though not specifically elaborated for this family.
- **Body system:** Cardiovascular system (UBERON:0004535 cardiovascular system).
- **Tissue/cell level:** Cardiac muscle tissue; **cardiomyocytes** (CL:0000746) show hypertrophy, interstitial fibrosis (implicating cardiac fibroblasts, CL:0000057, in the fibrotic response), and abnormal nuclear architecture.
- **Subcellular level:** **Nucleus** (GO:0005634) — the chromatin/H3K4me3-reader complex and the abnormal nuclear morphology are the disease's defining subcellular lesion; extranuclear/cytoplasmic mislocalization of mutant GATAD1 was also observed.
- **Localization/laterality:** Left-ventricle-predominant dilation (typical of DCM generally); not applicable as a laterality question in the traditional sense (DCM is usually left-sided or biventricular, not asymmetric in the lateralization sense used for paired organs).

---

## 8. Temporal Development

- **Onset:** Adult-onset — ages 50, 53, and 57 years for the three homozygous individuals (no pediatric or congenital presentation reported), consistent with typical adult-onset genetic DCM rather than an early-onset severe cardiomyopathy.
- **Onset pattern:** Insidious (found via heart failure symptoms and echocardiography rather than acute presentation).
- **Progression:** Slow/indolent — the proband had EF 21% at diagnosis (age 50) and EF 25% at 24-year follow-up (i.e., stable-to-slightly-improved on therapy, not a downhill trajectory); her sister progressed from DCM diagnosis to atrial fibrillation requiring AV-node ablation over a multi-decade course but remained NYHA class II at last follow-up (23 years post-diagnosis).
- **Disease course pattern:** Chronic, stable-on-therapy rather than rapidly progressive or relapsing-remitting; the brother's intermediate phenotype (isolated LV enlargement) **never progressed** to overt DCM over the observation period, and he died from an unrelated cause (cancer) at 73.
- **Duration:** Chronic/lifelong once manifest; no spontaneous remission reported, but long survival on standard heart-failure pharmacotherapy (decades) without need for transplantation in the reported cases.
- **Critical periods:** None specifically identified for intervention timing beyond the general principle that guideline-directed medical therapy initiated at diagnosis (as was done here) is associated with prolonged stable survival.

---

## 9. Inheritance and Population

- **Epidemiology:** No formal prevalence/incidence estimate exists for CMD2B specifically — it has been reported in **exactly one family** (3 affected homozygotes) since its description in 2011, and subsequent screening of 273 additional unrelated DCM probands found no further GATAD1 mutations, suggesting the disorder is exceptionally rare, likely private to this or closely related pedigrees. (For context, dilated cardiomyopathy overall has an estimated prevalence around 1:2,500, and recent 7-major-market epidemiology forecasts estimate roughly 3 million diagnosed prevalent DCM cases across the US/EU4/UK/Japan combined in 2023 — but this reflects the DCM umbrella, not the GATAD1 subtype.)
- **Inheritance pattern:** **Autosomal recessive** — genome-wide linkage analysis under a recessive model identified the 7q21 locus with a peak multipoint LOD score of 3.1 (between markers D7S669 and D7S515), and disease segregated only in homozygotes.
- **Penetrance:** High/complete for at least an intermediate cardiac phenotype among homozygotes (3/3 showed at least isolated LV enlargement), though only 2/3 progressed to overt DCM — suggesting **incomplete penetrance for the full DCM phenotype** specifically, but essentially complete penetrance for some cardiac abnormality.
- **Expressivity:** Variable — ranging from severe DCM (proband, EF 21%) to moderate DCM (sister, EF 40%) to a subclinical/intermediate phenotype (brother, borderline EF 50%, no progression to failure).
- **Genetic anticipation:** Not applicable/not reported (not a repeat-expansion disorder).
- **Germline mosaicism:** Not reported/not applicable to this pedigree-level Mendelian finding.
- **Founder effects:** The family is of **northern European (Norwegian) ancestry**; whether S102P represents a Norwegian founder allele versus a private de novo-origin recessive allele has not been established in additional Scandinavian cohorts (a candidate area for further population screening).
- **Consanguinity:** Central to this family's presentation — the proband's parents were first cousins, which unmasked the rare homozygous recessive genotype; this is the textbook mechanism for autosomal recessive disease discovery in isolated pedigrees.
- **Carrier frequency:** Unknown/not estimated in general populations (no gnomAD/dbSNP-derived population allele frequency was reported in the literature reviewed); the mutation was undetected in 1,558 control chromosomes screened, consistent with very low carrier frequency even in ancestry-matched controls.
- **Population demographics:** Only documented in a single family of white, northern European (Norwegian) ancestry; no other affected populations, geographic clusters, sex ratio, or age-distribution data exist beyond this pedigree (2 affected females, 1 affected/intermediate male — too small a sample to draw a sex-ratio conclusion, though it is worth noting the unrelated transcriptomic finding of higher GATAD1 expression in female vs. male idiopathic DCM hearts, an intriguing but unconfirmed parallel).

---

## 10. Diagnostics

- **Clinical/imaging tests used in the reported family:** Standard transthoracic **echocardiography** (diagnostic for DCM — LV enlargement, reduced EF); this remains the primary imaging diagnostic modality for DCM generally, supplemented in contemporary practice by **cardiac MRI** (late gadolinium enhancement/LGE for fibrosis and arrhythmic risk stratification, per 2023 ESC cardiomyopathy guidelines) — not specifically reported as performed in this 2011-era case series but standard-of-care today.
- **Biopsy/histopathology:** Left ventricular endomyocardial biopsy in the proband showed moderate myocyte hypertrophy and mild focal interstitial fibrosis — nonspecific DCM histology; the study additionally performed **immunohistochemistry** for GATAD1 localization and assessment of nuclear morphology, which is a research-level (not routine clinical) diagnostic approach specific to this gene discovery.
- **Genetic testing:** The causal mutation was identified via a combination of **genome-wide linkage analysis / homozygosity mapping** (SNP-array based) and **whole-exome sequencing**, an approach specifically suited to consanguineous, autosomal-recessive-appearing pedigrees. In current clinical practice, GATAD1 would be included (if at all) only on **broad DCM gene panels** or whole-exome/genome sequencing given its ultra-rare, single-family evidence base — the 2023 ESC cardiomyopathy guidelines' core recommended DCM genes for first-line testing are LMNA, PLN, RBM20, and FLNC (with TTN also central), reflecting that GATAD1 is not among consensus first-tier DCM genetic-testing genes.
- **Screening in relatives:** Cascade screening of the extended pedigree (echocardiography + eventual targeted GATAD1 sequencing) identified 13 asymptomatic heterozygous carriers and 8 unaffected non-carriers — the practical demonstration that heterozygote carriers do not require ongoing cardiac surveillance for this specific recessive disease (contrasting with dominant DCM genes, where first-degree relatives of a proband are recommended to undergo ECG/echocardiography screening per ESC guidelines).
- **Differential diagnosis:** Standard DCM differential applies — ischemic cardiomyopathy, myocarditis, alcohol/toxin-induced, other genetic DCMs (LMNA, TTN, RBM20, FLNC, PLN, sarcomeric genes), infiltrative and metabolic cardiomyopathies — GATAD1-CMD2B would only be specifically suspected in an **autosomal-recessive-segregating, consanguineous pedigree** given its extreme rarity.

---

## 11. Outcome/Prognosis

- **Survival:** Notably favorable/indolent relative to many other genetic DCMs — the proband survived **>24 years** post-diagnosis on standard heart-failure medications without requiring transplantation; her sister survived **>23 years** post-diagnosis. Neither death reported (proband and sister) was attributed to the cardiomyopathy in the published follow-up; the brother's death (at 73, from cancer) was explicitly unrelated to his cardiac phenotype.
- **Mortality/morbidity:** No sudden cardiac death, transplantation, or heart-failure-related death was reported in this family — a relatively benign long-term course among the affected individuals, though the small sample size (n=3) limits generalizability.
- **Complications:** Persistent atrial fibrillation developed in one of the two overt-DCM cases, managed with AV-node ablation and pacemaker implantation — the only reported disease-related complication requiring an interventional procedure.
- **Functional status:** Both overt-DCM individuals remained at **NYHA class II** (mild symptomatic limitation) through decades of follow-up rather than progressing to NYHA III/IV or requiring advanced heart-failure therapies (LVAD/transplant).
- **Prognostic factors:** Given only 3 cases, no formal prognostic biomarkers or risk-stratification model specific to CMD2B exists; general DCM prognostic factors (EF, NYHA class, LGE on MRI, genotype) would apply by extrapolation, though the general genetic-DCM prognostic literature is dominated by data on LMNA, FLNC, and TTN, not GATAD1.

---

## 12. Treatment

**Pharmacotherapy (as actually used in the reported family — standard guideline-directed heart-failure therapy, not GATAD1-targeted therapy):**
- **Digoxin** — NCIT:C363 / general cardiac glycoside therapy for symptom/rate control.
- **Furosemide** — loop diuretic for volume management (NCIT: Pharmacotherapy, NCIT:C15986, with therapeutic_agent furosemide).
- **Carvedilol** — beta-blocker, guideline-directed heart-failure therapy (NCIT:C15986 Pharmacotherapy; therapeutic_agent: carvedilol).
- **Enalapril** — ACE inhibitor, guideline-directed heart-failure therapy.
- **Spironolactone** — mineralocorticoid receptor antagonist (MRA), guideline-directed heart-failure therapy.
- **Warfarin** — anticoagulation (indicated given atrial fibrillation risk in this family).

**Contemporary guideline-directed medical therapy (GDMT) for DCM/HFrEF generally, applicable by extrapolation since no GATAD1-specific trial exists):** ACEi/ARB or **ARNI** (sacubitril-valsartan), beta-blockers, MRAs, and **SGLT2 inhibitors** (now a pillar of the "four-pillar" HFrEF regimen per contemporary ACC/AHA/HFSA and ESC heart-failure guidelines) — all under NCIT:C15986 Pharmacotherapy with the relevant therapeutic_agent CHEBI/NCIT term.

**Device/procedural therapy:**
- **AV-node ablation with pacemaker implantation** — performed in the sister for rate control of persistent atrial fibrillation (NCIT:C15329 Surgical Procedure / cardiac electrophysiology procedure category).
- **ICD implantation** — not specifically reported as used in this family, but per 2023 ESC cardiomyopathy guidelines, is a "should be considered" recommendation in DCM/hypokinetic-nondilated-cardiomyopathy patients with LVEF <50% plus ≥2 risk factors (syncope, LGE on CMR, inducible monomorphic VT) — relevant general management context for CMD2B patients.
- **Cardiac transplantation** — the standard end-stage option for refractory DCM generally; not required in this family's reported course.

**Genetic counseling:** Central to management given the autosomal recessive, consanguinity-associated inheritance — cascade testing correctly identified carriers who require no cardiac surveillance (unlike relatives of dominant-DCM probands) and informs reproductive counseling for future consanguineous unions in the extended family (NCIT:C15240 Genetic Counseling).

**Experimental/targeted therapy:** None specific to GATAD1/CMD2B exists in ClinicalTrials.gov; the chromatin-mechanism insight (HDAC1/2–GATAD1 axis) raises a theoretical, unvalidated rationale for epigenetic-modulating agents (e.g., HDAC inhibitors) in heart failure broadly, but no clinical translation for this specific gene defect has been reported.

**Therapeutic modality mapping for KB curation:** All treatments used are `SMALL_MOLECULE` pharmacotherapy (digoxin, furosemide, carvedilol, enalapril, spironolactone, warfarin) except the AV-node ablation/pacemaker, which is `DEVICE`/`SURGERY`.

---

## 13. Prevention

- **Primary prevention:** Not applicable in the traditional sense (monogenic disease); the only "primary prevention" lever is **avoidance of consanguineous mating** in known-carrier families to prevent homozygosity, plus **preimplantation genetic diagnosis or prenatal testing** for known carrier couples once a familial GATAD1 variant is identified.
- **Secondary prevention/screening:** **Cascade genetic testing and echocardiographic screening** of first-degree relatives in an identified pedigree — as performed in the original family (17 adult descendants screened) — is the appropriate secondary-prevention/early-detection strategy; heterozygous carriers can be reassured they do not require ongoing cardiac surveillance specific to this recessive gene.
- **Tertiary prevention:** Standard heart-failure GDMT (as above) to prevent progression/complications once DCM is diagnosed; anticoagulation to prevent thromboembolic complications of atrial fibrillation.
- **Genetic counseling:** Recommended for all carrier-identified family members per general ESC clinical-consensus statements on genetic counseling in DCM (2023) and clinical care of DCM family members (2025) — pre- and post-test counseling, discussion of recessive inheritance implications (carriers unaffected; 25% recurrence risk for future children of two carrier parents), and reproductive options.
- **Public health/behavioral:** No disease-specific public health intervention exists; general DCM population-level prevention (avoidance of alcohol excess, cardiotoxic exposures, viral myocarditis prevention) does not specifically apply to this monogenic subtype.

---

## 14. Other Species / Natural Disease

- **Taxonomy of models used:** *Danio rerio* (zebrafish; NCBITaxon:7955) and *Mus musculus* (mouse; NCBITaxon:10090) — no naturally occurring GATAD1-associated cardiomyopathy has been reported in companion animals or wildlife (OMIA has no listed GATAD1 entry as of current literature).
- **Orthologous gene:** Mouse *Gatad1* (MGI:1914460); rat *Gatad1* (RGD:1562004); zebrafish *gatad1*. The mouse and human proteins are similarly sized (266 vs. 269 amino acids) with a conserved N-terminal zinc finger, supporting deep evolutionary conservation of the domain disrupted by S102P.
- **Comparative pathology:** As detailed in the Mechanism section, neither the mouse cardiomyocyte-specific knockout nor (at baseline) the zebrafish knockout reproduces the human recessive cardiomyopathy phenotype without added environmental/mechanical stress — an important comparative-biology caveat that the mouse and fish loss-of-function models do not fully recapitulate the human missense-driven, chromatin-mislocalization mechanism.
- **Zoonotic potential:** Not applicable (non-infectious, monogenic disease).

---

## 15. Model Organisms

| Model | Type | Genetic manipulation | Phenotype recapitulation | Key reference |
|---|---|---|---|---|
| Zebrafish (*Danio rerio*) | Whole-organism, in vivo | TALEN-generated frameshift null alleles (4-bp, 13-bp deletions in exon 2); also transgenic lines expressing human S102P | **No baseline phenotype**; under combined ethanol + high-cholesterol stress, developed reduced survival (mortality onset ~7 months), reduced swimming capacity, and induction of *nppb*/*vmhc* fetal cardiac stress genes. Authors interpret findings as consistent with a haploinsufficient mechanism; S102P-transgenic fish showed only a "tendency" toward heart-failure phenotypes (possible dominant-negative). | Ta et al., *J Cardiovasc Dev Dis* 2016 (PMID:28955713) |
| Mouse (*Mus musculus*) | Mammalian, cardiomyocyte-specific conditional knockout | Cre-lox cardiomyocyte-specific *Gatad1* deletion | **No cardiomyopathy** at baseline aging to 18 months or after pressure-overload (TAC) stress; no abnormal nuclear morphology (unlike human patient myocardium) — model **does not recapitulate** the human disease. | 2024 study, *J Mol Histol* (PMID:39641830) |
| Mouse, ischemia-reperfusion context | Mammalian, cardiomyocyte-specific knockout/manipulation | Gatad1 knockdown/knockout in the setting of I/R injury | Gatad1 modulates fatty-acid oxidation (*Acaa2*, *Acadm*) vs. glucose oxidation (*Pdha1*) gene transcription and cardiomyocyte apoptosis after ischemic injury; mediates SPC-induced cardioprotection — a **stress-inducible metabolic role**, not baseline cardiomyopathy. | 2024–2025, *Free Radical Biology and Medicine* / ScienceDirect |

**Model limitations (synthesis):** The available animal models collectively suggest that **simple GATAD1 loss-of-function is insufficient** to reproduce the human recessive cardiomyopathy at baseline in mammals; the human disease likely requires either (a) the specific missense/mislocalization mechanism (S102P) rather than null alleles, (b) aging/time-courses beyond what has been tested, (c) additional physiological stress, or (d) non-cardiomyocyte-autonomous contributions (e.g., interaction with other H3K4me3-complex members, HDAC1/2 co-dependency) not captured by cardiomyocyte-restricted knockouts. This is a strong candidate for a `HUMAN_MODEL_MISMATCH` discussion block in any dismech curation of this entry, given that the mouse model explicitly failed to reproduce even the histologic (nuclear morphology) hallmark of the human disease.

---

## Curation Notes for dismech Entry

1. **Extreme evidence sparsity:** All disease-specific clinical data derive from one 2011 paper describing one family (PMID:21965549) — curation should rely heavily on this single primary source, cross-checking every quoted snippet directly against the cached abstract/full text per SOP, and clearly flag `evidence_source: HUMAN_CLINICAL` for the family data vs. `MODEL_ORGANISM` for the zebrafish/mouse data.
2. **NEC risk:** GATAD1 is occasionally miscited in aggregator databases (GeneCards) as linked to Heimler Syndrome 1 — verify against MONDO/OMIM #234580 (PEX1/PEX6) before using any DR-tool output referencing "GATAD1 + Heimler," and treat any such report as NEC-suspect per the project's NEC preflight protocol.
3. **HUMAN_MODEL_MISMATCH candidates:** Both the zebrafish (requires added ethanol/cholesterol stress; possible haploinsufficiency vs. dominant-negative ambiguity) and mouse (no phenotype at all in cardiomyocyte-specific KO) models are strong candidates for this discussion `kind`, given direct textual evidence that the mouse model failed to reproduce the human nuclear-morphology hallmark.
4. **Mechanism module fit:** The GATAD1/H3K4me3/HDAC1-HDAC2 axis could potentially be framed using the existing `cardiomyopathy_maladaptive_remodeling` module (HP:0001638) as a conforming node, substituting an epigenetic/chromatin-reader trigger for the more typical structural/contractile trigger.
5. **Digenic/oligogenic:** Not applicable — this is a single-gene, single-locus recessive disease.

---

### Sources
- [Homozygosity mapping and exome sequencing reveal GATAD1 mutation in autosomal recessive dilated cardiomyopathy - PubMed (PMID:21965549)](https://pubmed.ncbi.nlm.nih.gov/21965549/)
- [Homozygosity Mapping and Exome Sequencing Reveal GATAD1 Mutation — PMC full text](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3248690/)
- [OMIM #614672 — CARDIOMYOPATHY, DILATED, 2B; CMD2B](https://omim.org/entry/614672)
- [OMIM *614518 — GATA ZINC FINGER DOMAIN-CONTAINING PROTEIN 1; GATAD1](https://omim.org/entry/614518)
- [GATAD1 Gene - GeneCards](https://www.genecards.org/cgi-bin/carddisp.pl?gene=GATAD1)
- [Cardiomyopathy, Dilated, 2b - MalaCards](https://www.malacards.org/card/cardiomyopathy_dilated_2b_2)
- [Modeling GATAD1-Associated Dilated Cardiomyopathy in Adult Zebrafish (PMID:28955713)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5611887/)
- [Loss of GATAD1 in cardiomyocyte does not cause cardiomyopathy in mice (PMID:39641830)](https://pubmed.ncbi.nlm.nih.gov/39641830/)
- [GATAD1 is involved in sphingosylphosphorylcholine-attenuated myocardial ischemia-reperfusion injury - ScienceDirect](https://www.sciencedirect.com/science/article/abs/pii/S0891584924010980)
- [Recruitment of the Mammalian Histone-modifying EMSY Complex to Target Genes Is Regulated by ZNF131 - PubMed](https://pubmed.ncbi.nlm.nih.gov/26841866/)
- [Heimler Syndrome Is Caused by Hypomorphic Mutations in the Peroxisome-Biogenesis Genes PEX1 and PEX6 - PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC4596894/)
- [OMIM #234580 — HEIMLER SYNDROME 1](https://omim.org/entry/234580)
- [2023 ESC Guidelines for Management of Cardiomyopathies - ACC](https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2023/08/30/02/53/2023-esc-guidelines-for-cardiomyopathies-esc-2023)
- [Genetic counselling implementation in dilated cardiomyopathy: ESC clinical consensus statement](https://dx.doi.org/10.1093/eurheartj/ehag159)
- [Dilated Cardiomyopathy (DCM) - Epidemiology Forecast to 2032 - DelveInsight](https://www.delveinsight.com/report-store/dilated-cardiomyopathy-dcm-epidemiology-insights)
- [Human cardiac-specific cDNA array for idiopathic dilated cardiomyopathy: sex-related differences - Physiological Genomics](https://journals.physiology.org/doi/full/10.1152/physiolgenomics.00265.2007)
- [dilated cardiomyopathy MONDO:0005021 - Monarch Initiative](https://monarchinitiative.org/MONDO:0005021)